Background: Subconjunctival hemorrage (SCH) is a frequent, mild bleeding manifestation and a common cause of consultation. Hemostatic alterations are possible causes of SCH but their role and prevalence is unknown. We assessed the prevalence of hemostatic abnormalities in patients with spontaneous, recurrent SCH to clarify the role of the hemostasis laboratory in this clinical setting. Methods: A total of 105 SCH patients (21-78 years, 65 females) with no identifiable cause (hypertensiontrauma-conjunctivitis) or concomitant treatments (NSAIDsaspirin-oral anticoagulants-antiplatelet agents) and 53 age and sex-matched healthy controls (HCs) (22-72 years, 29 females) were evaluated for skin bleeding time, PFA-100
Introduction
Subconjunctival hemorrage (SCH) is a common bleeding manifestation that leads to frequent access to eye care clinics and is a cause of concern for patients and their general practitioners [1, 2] . SCH is one frequent cause of acute ocular redness [3] , conventionally defined as the red eye, the most common ocular disorder in primary care [1, 2] . SCH are characterized by the sudden, often spontaneous, appearance of an area of bleeding under the conjunctiva. The diagnosis is based on the observation of a clear red area, usually unilateral, localized and sharply circumscribed, with the underlying sclera not visible and the adjacent conjunctiva free of inflammation, and no discharge [1] . Besides trauma, acute hemorrhagic conjunctivitis and hypertension are the main causes of SCH, but a high percentage of SCH remain unexplained [4] .
Although bleeding disorders are usually listed among the possible causes of SCH [1, 2, 4, 5] , their role and prevalence in patients with SCH has not been systematically investigated so far. One previous study suggested that the blood clotting factor FXIII-Val-34Leu polymorphism predisposes to idiopathic SCH [6] . Despite scanty evidence for a role of hemostatic defects in the etiology of SCH, several authors consider it mandatory to study hemostasis in recurrent SCH [2, 4, 7] .
Given that previous studies in patients suffering from other mild, recurrent mucocutaneous bleeding symptoms, such as unexplained menorrhagia or recurrent epistaxis, have revealed a high prevalence of previously undiagnosed inherited bleeding disorders, like von Willebrand disease or inherited platelet function disorders [8] [9] [10] [11] [12] [13] [14] , an investigation on the frequency of hemostatic abnormalities in subjects with recurrent spontaneous SCH seemed warranted.
Aim of the present study was to evaluate the prevalence of congenital or acquired bleeding disorders in patients with spontaneous, recurrent SCH and to clarify the role of the hemostasis laboratory in the diagnostic work-up of SCH.
Materials and methods

Subjects
Consecutive patients referred to the Eye Clinic, Division of Ophtalmology of the Perugia hospital, for a red eye during a 2-year period were studied. Eligible patients had to have at least two episodes of spontaneous SCH in the absence of identifiable causes (trauma, conjunctivitis, poorly controlled hypertension), no other spontaneously reported bleeding symptoms and no concomitant treatments affecting platelet function or blood coagulation (aspirin, antiplatelet agents, heparin, oral anticoagulants, anti-vitamin K or NOACs, NSAIDs) or chronic use of steroids.
A series of consecutive healthy controls (HCs), age-and sexmatched, without a history of SCH or of other hemorrhagic symptoms, selected among patients undergoing consultation for non-hemorragic ocular disorders in the same period or among laboratory or hospital personnel, were enrolled according to the same exclusion criteria as the SCH patients and underwent the same studies.
Blood pressure history, concomitant treatments and active daily living habits were collected by personal interview. Personal and family bleeding history was also evaluated using a standardized bleeding assessment tool (BAT) [15] . The study was approved by the Local Ethical Committee (CEAS Umbria, Prot N. 22703/09/ON) and written informed consent was obtained from all participants.
Bleeding time
A standardized template bleeding time was performed as previously described using an automatic template device (Surgicutt; International Technidyne Corporation, Edison, NJ, USA). The mean bleeding time was calculated from the two cuts [16] .
Blood collection
Blood was collected in 3.8% sodium citrate (1:10 v/v) or in EDTA in the morning, under fasting conditions using a 20-gauge butterfly needle and discarding the first 2 mL of blood [17] .
Laboratory tests
Platelet count: EDTA blood samples were utilized to count platelets by a HeCo S automatic counter (Seac-Radim Company, Florence, Italy) [18] . Blood clotting screening: Prothrombin time (PT) was measured by using the RecombiPlasTin 2G reagent, activated partial thromboplastin time (aPTT) using the SyntASil reagent, the thrombin clotting time using the HemosIL ThrombinTime reagent and fibrinogen using the Clauss method with the QFA Thrombin reagent (all from Instrumentation Laboratory, Bedford, MA, USA) by an automated ElitePro coagulometer (Instrumentation Laboratories) in plateletpoor plasma (PPP) [19] .
Light transmission aggregometry (LTA): Platelet aggregation was assessed with an optical aggregometer (APACT-4, Helena Biosciences Europe, Sunderland, UK), as previously described [20] . In brief, whole blood was centrifuged at 150 g or 1000 g for 10 min to obtain plateletrich plasma (PRP) and PPP, respectively. Platelet aggregation was studied in unadjusted PRP samples and was followed for 5 min. Agonists concentrations were: epinephrine, 10 and 100 μM; ADP, 2 and 10 μM; U46619, 2 μM; arachidonic acid (AA), 1 mM; collagen, 2 μg/mL; ristocetin, 0.6-1.5 mg/mL [21] .
Epinephrine, ADP, collagen type III from equine tendon and ristocetin were purchased from Mascia Brunelli (Milan, Italy), while AA sodium salt, from porcine liver, and the thromboxane A2 receptor agonist U46619 were from Sigma Aldrich (Saint Louis, MO, USA).
PFA-100: PFA-100
® (Siemens Healthcare Diagnostic, Marburg, Germany) was performed using collagen/epinephrine (C/Epi) and collagen/ADP (C/ADP) cartridges. The time required to stop blood flow, defined as closure time (CT), was measured [22] .
Blood clotting factor and VWF assays: FVIII:C levels were measured using factor-deficient plasma (Instrumentation Laboratories, Bedford, MA, USA). FXIII antigen levels were measured using an automated latex-enhanced immunoassay (Factor XIII HemosIL, Instrumentation Laboratories) on an automated Elite Pro coagulometer. FXIII activity was determined by a photometric assay using a Berichrom kit (Dade Behring, Marburg, Germany) [23] . Von Willebrand factor antigen (VWF:Ag) was measured by an enzyme-linked immunosorbent assay (ELISA) using a polyclonal antiserum (Asserachrom VWF, Diagnostica Stago, Asnières-sur-Seine, France). VWF ristocetin cofactor activity (VWF:RCo) was measured by LTA (Helena Bioscience Europe, Sunderland Enterprise Park, UK) [24] .
Statistical analysis
Results are expressed as means and 95% confidence intervals (CIs). Differences between controls and patients were analyzed by using the ANOVA or the χ 2 -test. A p-value of < 0.05 was considered as statistically significant. Correlation analyses were carried out with the Spearman's correlation test [25] . 
Results
Characteristics of the study population
Bleeding time and PFA-100
One SCH case and 0 controls had a bleeding time above the normal range (3-10 min) (χ 2 = 0.12, p = 0.73) (Supplemental Data, Table 1 that accompanies the article at http://www. degruyter.com/view/j/cclm.2016.54.issue-1/cclm-2015-0274/cclm-2015-0274.xml?format=INT). The average bleeding time values in the two groups did not differ ( Figure 1 ). In total 12 SCH cases (11.42%) and five controls (9.43%) had a C/EPI-CT above the normal range (χ 2 = 0.0121, p = 0.91) (Supplemental Data, Table 1 ). The average C/EPI-CT did not differ between the two groups ( Figure 1) . One of the SCH cases (0.9%) and none of the controls (0%) had a C/ADP-CT above the normal range (χ 2 = 0.12, p = 0.73) (Figure 1 ; Supplemental Data, Table 1 ). The average C/ADP-CT did not differ between the two groups ( Figure 1 ).
Blood clotting assays
Average aPTT, PT, TcT, fibrinogen values and platelet count did not differ between the two groups (Supplemental Data, Table 1 ; Supplemental Data, Figure 1 ). Four SCH cases (3.81%) and one control (1.88%) had coagulation factor parameters below the normal range (χ 2 = 0.029, p = 0.86) (Figure 2 ; Supplemental Data, Results). Average FVIII levels, FXIII Ag and FXIII activity levels did not differ between the two groups ( Figure 2 ). One SCH case (0.9%) and 0 controls (0%) had VWF:Ag levels below the normal range (χ 2 = 0.12, p = 0.73). Average VWF:Ag and VWF:RCo did not differ between the two groups ( Figure 2 ). 
Diagnoses among all cases
One patient with recurrent SCH (0.95%) and none of the controls (0%) were diagnosed a type I von Willebrand disease (Table 2 ), a prevalence not significantly different between the two groups (χ 2 = 0.12, p = 0.73). The BSS in the VWD patient was 4. When excluding this patient from the SCH group, average RIPA no longer differed between the two groups. No other cases with a consistent pattern orienting towards a specific congenital or acquired blood clotting disorder were observed (Supplemental Data, Table 1 ).
The number of SCH recurrences inversely correlated with the platelet count (r = −0.2, p = 0.04) and directly with patients' age (r = 0.29, p = 0.003).
Discussion
Our study shows that the prevalence of hemostatic alterations in patients with recurrent, spontaneous SCH is not different from that in the general population. We studied both platelet function and VWF, for the identification of possible mucocutaneous bleeding disorders, as well as blood clotting tests and factor VIII, for the detection of possible plasma coagulation disorders. Factor XIII antigen and factor XIII activity were also measured because a previous study reported a higher prevalence of the FXIII Val34Lev polymorphism in patients with spontaneous SCH [6] and considering that this polymorphism influences FXIII activity [26] , but we observed no significant difference between SCH patients and controls.
SCH cases Controls
Isolated, minor abnormalities of hemostatic parameters were observed both in the SCH and in the HC groups, but most of these were aspecific and compatible with the variability of blood clotting assays. In particular, abnormal low dose ADP-and epinephrine-induced aggregation, the abnormality most often detected in our study, is frequently found in healthy, non-bleeder individuals [8] .
The diagnosis of mild mucocutaneous bleeding disorders is cumbersome [8, 27] , therefore bleeding history was evaluated, with the help of a bleeding assessment tool Normal ranges (horizontal dotted lines) were obtained from 30 normal subjects not related to the current study but tested in our laboratory in the same period for the determination of the internal laboratory normal ranges. No significant differences between controls and SCH were observed except for RIPA (p = 0.04). proven to contribute to the identification of mild mucocutaneous bleeders [15] , and a series of first and second level hemostatic tests were carried out, as recommended in the approach to patients with a suspected inherited bleeding disorder [28] , but no imbalance in the prevalence of hemostatic alterations was found. The diagnosis of mild, type-I von Willebrand disease in one out of 105 SCH patients studied is compatible with the prevalence of VWD in the general population [29] .
No studies have previously prospectively and systematically addressed the possible role of hemostatic alterations in SCH, to the best of our knowledge. Our results show that hemostatic screening or second level blood clotting tests are of no value in patients with recurrent SCH without other bleeding symptoms and that hemostatic alterations are not a significant cause of conjunctival hemorrhage. Despite no evidence that SCH is more frequent in patients with hemostatic impairment as compared with the general population, hemostatic screening is still widely recommended in the diagnostic work-up of SCH patients [2, 4, 7] , and even in the most recent version of the ISTH bleeding assessment tool conjunctival hemorrhage is still listed among other bleedings contributing to raise the bleeding score [30] . Our data, in a relatively large and well characterized series of patients with recurrent SCH and no confounding variables, show that there is no role for the hemostasis laboratory in the identification of the causes of SCH and that most probably local factors, as well as arterial hypertension, are the major causes of SCH [1] [2] [3] [4] [5] 31] .
Given that the red eye represents one of the most common ocular disorders in primary care and a very frequent cause of access to oculistic first aid [1] [2] [3] [4] [5] , the avoidance of useless hemostatic laboratory testing may reduce unnecessary costs to the health systems.
It has been suggested that the use of a structured questionnaire to derive a bleeding score may be more helpful for the detection of bleeding disorders than laboratorybased screening tests [15, 30] : our results showing that the bleeding score in one SCH case turning out to be affected by VWD (BSS = 4) was higher than in the rest of the SCH population without hemostatic abnormalities (average BSS = 0.81, 95% CI 0.59-1.02) suggest that the systematic application of a bleeding assessment tool to recurrent SCH patients may be more cost-effective than the use of hemostatic screening tests; this, however, requires validation in a specifically designed prospective study.
Our study has some possible limitations: first, the populations studied may not be large enough to demonstrate an imbalance in the prevalence of hemorrhagic disorders in SCH as compared to HCs. However, our study population was reasonably large and it is unlikely that a clinically relevant increase of the prevalence of bleeding disorders in the SCH group would have been missed; moreover, in previous similar studies in patients with unexplained minor bleeding symptoms in which an imbalance in the prevalence of hemorrhagic disorders was actually shown, a diagnosis of bleeding disorder was made in 10.7%-48% of patients [8, [10] [11] [12] [13] , and this would not have been missed with the number of subjects we studied. Second, the selection of controls could have led to bias. However, the controls were perfectly matched for age and sex, and many of them were recruited among patients seeking oculistic consultation for non-hemorrhagic ocular problems, therefore from a population very homogeneous with that with SCH. Third, some of the screening tests applied, like the PFA-100 ® and the skin bleeding time, have low sensitivity and specificity and are no longer recommended for the assessment of inherited bleeding disorders [28] . However, these tests are still largely used worldwide in the first assessment of subjects with suspected bleeding disorders [27] , and moreover they were applied in association with more sensitive and validated assays. Finally, the BAT we applied has been previously validated only for the diagnosis of von Willebrand disease [30] and, in small case series, of inherited platelet function disorders [32, 33] , therefore it may not apply to other conditions potentially associated with SCH incidence.
In conclusion, in patients with recurrent, spontaneous SCH the prevalence of hemostatic alterations is not different from the general population, and a hemostatic screening or second level blood clotting tests are of no use and certainly not cost-effective in this population.
